Fagron NV

Fagron NV is a leading global pharmaceutical compounding company dedicated to optimizing and innovating personalized medicine. The company's mission is to improve personalized medicine and make it more accessible for patients, thereby significantly impacting global health and welfare. While governed by Belgian law with a registered office in Waregem, Belgium, its operational headquarters are located in Rotterdam, Netherlands.

Fagron offers a comprehensive range of products and services across three main segments: Essentials, Brands, and Compounding Services. The Essentials segment provides pharmaceutical raw materials, compounding equipment, packaging, and supplies. The Brands segment focuses on semi-finished products, pharmaceutical-grade vehicles, and pharmacogenomic testing. Compounding Services include sterile and non-sterile compounding, as well as outsourcing for pharmacies and hospitals. Fagron serves a diverse customer base, including independent and chain pharmacies, hospitals, clinics, prescribers, research institutions, and laboratories across more than 35 countries in EMEA, North America, and Latin America.

Under the leadership of CEO Rafael Padilla, Fagron has demonstrated strong financial performance, reporting 9.2% topline growth and a 10.9% increase in REBITDA for FY 2025. Recent strategic moves include acquisitions like Amber Compounding Pharmacy in Singapore/Malaysia and Vepakum, a packaging manufacturer in Brazil, alongside securing a license for its Anazao Health facility in Tampa to expand compounded medication shipments to California. The company's strategic plan for 2025-2030 emphasizes strengthening its leadership in Essentials, accelerating growth in Brands, expanding sterile compounding services, and optimizing non-sterile compounding, aiming to maintain its position as a top-three global player in pharmaceutical compounding.